Second-line pembrolizumab versus chemotherapy in Japanese patients with advanced esophageal cancer: subgroup analysis from KEYNOTE-181.

Kei MuroTakashi KojimaToshikazu MoriwakiKen KatoFumio NagashimaHisato KawakamiRyu IshiharaTakashi OgataTaroh SatohKeiichi IwakamiShirong HanNaoyoshi YatsuzukaTomoko TakamiPooja BhagiaToshihiko Doi

Published in: Esophagus : official journal of the Japan Esophageal Society (2021)

Consistent with the global trial results, second-line pembrolizumab therapy showed a survival benefit and a favorable safety profile compared with chemotherapy in Japanese patients with advanced esophageal cancer.

Keyphrases

locally advanced
phase iii
advanced non small cell lung cancer
phase ii
clinical trial
study protocol
squamous cell carcinoma
randomized controlled trial
chemotherapy induced
free survival
mesenchymal stem cells
rectal cancer
open label
radiation therapy
data analysis